Australia
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
1.74
|
June 30, 2024 | USD 2.33 | 0.08% |
|
Australia |
|
2 |
0.70
|
June 30, 2024 | USD 169.95 | -0.56% |
|
Australia |
|
3 |
0.56
|
June 30, 2024 | USD 0.74 | 0.62% |
|
Australia |
|
4 |
0.25
|
June 30, 2024 | USD 1.90 | -4.74% |
|
Australia |
|
5 |
0.21
|
June 30, 2024 | USD 1.23 | -0.40% |
|
Australia |
|
6 |
0.12
|
Dec. 31, 2023 | USD 18.33 | -0.84% |
|
Australia |
|
7 |
0.08
|
Dec. 31, 2023 | USD 6.16 | 2.82% |
|
Australia |
|
8 |
0.02
|
June 30, 2024 | USD 0.74 | 1.48% |
|
Australia |
|
9 |
0.01
|
June 30, 2024 | USD 2.09 | 0.97% |
|
Australia |
|
10 |
0.00
|
June 30, 2024 | USD 7.27 | 0.71% |
|
Australia |
The Clinical Trials company in Australia with the highest Debt to Equity Ratio is Australian Clinical Labs Limited (ASX: ACL.AX) at 1.74.
The Clinical Trials company in Australia with the lowest Debt to Equity Ratio is Clinuvel Pharmaceuticals Limited (ASX: CUV.AX) at 0.00.
The top 10 Clinical Trials companies in Australia by Debt to Equity Ratio are Australian Clinical Labs Limited, CSL Limited, Monash IVF Group Limited, Mesoblast Limited, PolyNovo Limited, Telix Pharmaceuticals Limited, Anteris Technologies Ltd, Cogstate Limited, Immutep Limited and Clinuvel Pharmaceuticals Limited.
The bottom 10 Clinical Trials companies in Australia by Debt to Equity Ratio are Clinuvel Pharmaceuticals Limited, Immutep Limited, Cogstate Limited, Anteris Technologies Ltd, Telix Pharmaceuticals Limited, PolyNovo Limited, Mesoblast Limited, Monash IVF Group Limited, CSL Limited and Australian Clinical Labs Limited.